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Abstract
Parkinson’s disease (PD) is a rather common movement disorder as a result of the 
degeneration of dopaminergic neurons within the substantianigra. Current treatments for PD 
afford symptomatic relief with no prevention of disease progression. Due to the neuroprotective 
and anti-apoptotic potential of the isoquinoline alkaloid berberine (BBR), this study was 
conducted to assess whether BBR pretreatment could attenuate behavioral and neuronal 
derangement in 6-hydroxydopamine (6-OHDA)-induced model of PD in the rat. Unilateral 
intrastriatal 6-OHDA-lesioned rats received BBR at doses of 25 and/or 50 mg/kg (i.p.) three 
times at an interval of 24 h, started 2 days before the surgery. After 1 week, apomorphine 
caused significant contralateral rotations and a significant reduction in the number of Nissl-
stained and tyrosine-hydroxylase (TH)-positive neurons on the left side of the substantianigra. 
BBR pretreatment at a dose of 50 mg/kg significantly reduced rotations and prevented loss of 
TH-positive neurons. These results indicate pre-lesion administration of BBR could protect 
against 6-OHDA toxicity and this may be of benefit besides other available therapies in PD.
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Introduction
Parkinson’s disease (PD) is due to 
degeneration of dopaminergic neurons in 
the mesencephalicsubstantianigra. Clinical 
debilitating manifestations of PD include resting 
tremor, muscle rigidity, postural imbalance, 
an inability to initiate movements, and a 
lack of facial expression (1). The neurotoxin 
6-hydroxydopamine (6-OHDA) has routinely 
been used to injure nigral dopaminergic 
neurons. Intrastriatal injection of 6-OHDA has 
been used as one of the valuable models of PD 
(2). Activity of tyrosine hydroxylase (TH), the 
rate-limiting enzyme in the synthesis of the 
dopamine, progressively decreases following 
the loss of dopaminergic neurons in PD (3). 
Intracerebral injection of 6-OHDA also leads 
to apoptotic cell death of dopaminergic neurons 
in the substantianigra, thus, it is implicated in 
the pathogenesis of Parkinson’s disease (4, 5). 
Meanwhile, oxidative stress-induced neuronal 
death plays a pivotal role in pathogenesis 
of neurodegenerative disorders like PD (6). 
Currently, treatment of PD is symptomatic and 
begins with levodopa or dopamine agonists, 
depending on age and neuropsychiatric 
symptoms (7). Nevertheless, after a certain time 
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Sciences (Tehran, Iran). The animals were 
held in the colony room for at least one week 
before being tested. Those rats with net rotations 
less than 30/hour following intraperitoneal 
injection of apomorphine hydrochloride (2 mg/
kg; Sigma Chemical, USA) according to an 
earlier study (6) were selected for the present 
study. The animals were randomly divided 
into six groups: sham-operated, BBR25 and 
BBR50-treated sham-operated groups, lesion 
group (6-OHDA) and BBR25 and BBR50-
treated lesion groups (6-OHDA + BBR25 and 
6-OHDA + BBR50). Unilateral intrastriatal 
6-OHDA (Sigma Chemical, USA) injection (left 
side) was performed through a 5 µl Hamilton 
syringe on anesthetized rats (ketamine 80 mg/
kg and xylazine8 mg/kg, i.p.) using stereotaxic 
apparatus (Stoelting, USA) at the coordinates: 
L–3 mm, AP + 9.2 mm, V + 4.5 mm from the 
center of the interaural line, according to the 
atlas of Paxinos and Watson (16). At the end 
of injection, the needle was left in place for an 
additional 5 min and then withdrawn at a rate of 
1 mm/min. The lesion group received a single 
injection of 5 µl of 0.9% saline containing 2.5 
µg/µl of 6-hydroxydopamine-HCL (Sigma 
Chemical, USA) and 0.2% ascorbic acid (W/V) 
at a rate of 1 µl/min. The sham group received 
an identical volume of ascorbate-saline solution. 
The 6-OHDA + BBR25 and 6-OHDA + BBR50 
groups received the neurotoxin in addition 
to BBR IP dissolved in propylene glycol 
(Merck, Germany) at doses of 25 or 50 mg/kg, 
respectively. BBR (Sigma Chemical, USA) was 
daily administered, started two days before the 
surgery, with the last injection being 1 h before 
the surgery.
Behavioral evaluation
The animals were tested for rotational 
behavior by apomorphine hydrochloride (2 mg/
kg, i.p.) one week before surgery (baseline) 
and after 1 week. The rotations were measured 
according to a method as described previously 
(2). Briefly, the animals were allowed to habituate 
for 10 min and then 1 min after the injection, full 
rotations were counted in a cylindrical container 
(a diameter of 33 cm and a height of 35 cm) at 
10-min intervals for 60 min in a dimly-lighted 
and quiet room. Net number of rotations was 
period, most of the patients experience some 
side effects including motor and non-motor 
fluctuations and dyskinesia (8).
Natural compounds with antioxidant activity 
from plants were reported to reduce oxidative 
stress burden via scavenging reactive oxygen 
species, to chelate deleterious metal ions like 
iron and to diminish inflammation and in this 
way could attenuate nigrostriatal dopaminergic 
neuronal loss in PD (9). Berberine (BBR) is 
a benzyl tetra isoquinoline alkaloid and the 
primary pharmacological active constituent of 
Coptidisrhizoma, which could inhibit neuronal 
apoptosis in cerebral ischemia (10). Chronic 
BBR treatment of streptozotocin-diabetic 
rats could ameliorate learning and memory 
impairment due to improvement of synaptic 
dysfunction and anti-apoptotic property (11). 
BBR also protects against ischemic brain injury 
by decreasing oxidative stress and inhibiting 
mitochondrial apoptosis (12). BBR is also a 
potent suppressor of neuroflammation and could 
be of therapeutic potential for the treatment of 
neurological and neurodegenerative diseases like 
Alzheimer’s disease (13). Post-lesion treatment 
of 6-hydroxydopamine (6-OHDA)-lesioned 
rats with BBR did not show any improvement 
in apomorphine-induced rotations and was 
not capable of restoring dopamine level and 
tyrosinehydroxylase level (14). In contrast, BBR 
has been able to protect human dopaminergic 
neuronal cells against 6-OHDA neurotoxicity 
through the induction of heme oxygenase-1 
(15). Thus, the present study was undertaken 
to investigate theneuroprotective effect of pre-
lesion BBR treatment in 6-OHDA induced 
model of PD using behavioral and histochemical 
methods.
Experimental
Animals
Adult male Wistar rats, weighing 210-260 
g (n = 60) (procured from Pasteur’s Institute, 
Tehran) were housed in a temperature-controlled 
colony room under light/dark cycle with free 
access to food and water. The used procedures 
for animals and their care were according to NIH 
guidelines and the protocol was approved by 
Ethics committee of Iran University of Medical 
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defined as the contralateral scores minus the 
ipsilateralones.
Histochemical study
At the end of the study, the rats were deeply 
anesthetized with a high dose of ketamine (150 
mg/kg) and perfused through the ascending 
aorta with 50-100 ml of 0.9% saline followed by 
100-150 ml of fixative solution containing 4% 
paraformaldehyde in 0.1 M phosphate buffer 
(PB, pH 7.4) followed by 100 ml of 0.1 M PB. 
Following perfusion, the brains were removed 
from the skull, blocks of forebrain and brainstem 
were prepared, and after final steps of preparation 
(immersion in 30% sucrose solution for 1-2 
days), sections were cut at a thickness of 30 
µm on a freezing microtome (Leica, Germany) 
and collected in PB (0.1 M). Every second 
section was Nissl-stained with 0.1% cresyl 
violet (Sigma). The other sections were used for 
tyrosine hydroxylase immunohistochemistry.
Tyrosine hydroxylase (TH) immunohistochemistry
Tyrosine hydroxylase (TH) is the rate 
limiting enzyme for dopamine synthesis 
and is usually used as a selective marker of 
dopaminergic neurons. The sections on gelatin-
coated slides were incubated in 0.1% sodium 
borohydride in phosphate-buffered saline (PBS, 
pH 7.4), methanol containing 0.03% H2O2, 
then in Triton X100 (0.03%) and 0.1% bovine 
serum albumin in PBS, with rinsing 2-3 times 
between the steps in a humidified chamber at 
darkness at room temperature. Then, sections 
were incubated with primary polyclonal rabbit 
anti-TH antibody (1/200) in PBS at darkness 
overnight and then with secondary anti-rabbit 
IgG-peroxidase antibody (HRP bound) raised in 
goat (1/200) in PBS for two hours. To reveal the 
bound peroxidase, the sections were incubated in 
diaminobenzidinetetrahydrochloride (10 mg/20 
ml of PBS and 0.03% H2O2) for 5-8 min, rinsed, 
dehydrated, cleared and coverslipped.
Histological evaluation
For each animal, mesencephalic sections 
(interaural 2.9-4.2 mm) were examined by a 
method as described previously (6). Briefly, 
Nissl-stained neurons and TH-positive neurons 
of the SNC were manually counted (Light 
microscopy; X400) using a superimposed grid 
to facilitate the procedure. At least two sections 
representative of each of four Paxinos-Watson 
planes (4.2, 3.7, 3.2, 2.97; Interaural) were 
examined by scanning the entire extent on each 
side. Counting was done blind to the treatments 
received.
Statistical analysis
All data were expressed as means± standard 
error. For statistical evaluation of rotational 
behavior and histochemical data, the parametric 
one-way ANOVA test followed by Tukey’spost-
hoc test was used. In all analyses, the null 
hypothesis was rejected at a level of 0.05.
Results and Discussion
The beneficial effect of BBRat doses of 25 
and 50 mg/kg was evaluated on apomorphine-
induced rotations for a period of 1 hour (Figure 
1). There were no significant differences among 
Figure 1. Total net number of apomorphine-induced rotations/1 h after 1 week in sham (upper panel) and 6-OHDA (lower panel) groups.
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the groups at baseline (before surgery). Statistical 
analysis of the total net number of rotations 1 
week after the surgery showed that apomorphine 
caused a very significant contralateral turning 
in the rats of 6-OHDA-lesioned group (p < 
0.0001) and induced less significant rotations 
in 6-OHDA + BBR25 and 6-OHDA + BBR50 
groups (p < 0.0005 and p < 0.005, respectively) 
in comparison with Sham group. Moreover, the 
group 6-OHDA + BBR50 showed a significant 
reduction of rotations (p < 0.05) when compared 
to 6-OHDA-lesioned group.
The positive values indicate contralateral 
rotations. 6-OHDA stands for the neurotoxin 
6-hydroxydopamine. # p < 0.05 (versus 
6-OHDA).
The results of histochemical studies in Nissl 
staining (Figure 2) showed that there is no 
significant difference amongst sham, sham + 
BBR25, and sham + BBR50 groups regarding 
the number of Nissl-stained neurons on the left 
side of SNC. In addition, a significant reduction 
was noticed in 6-OHDA-lesioned group (p < 
0.01) and there wasnosignificant reduction in 
6-OHDA + BBR50 when compared to sham 
group. In this respect, the number of Nissl-
stained neurons on the left side of SNC was 
significantly higher in 6-OHDA + BBR50 versus 
6-OHDA-lesioned group (p < 0.05).
Photomicrographs show Nissl-stained 
neurons in coronal sections through the midbrain 
in experimental groups. A severe reduction in the 
number of neurons in SNC was observed in the 
6-OHDA-lesioned group, but no such marked 
reduction was noted in the BBR50-pretreated 
6-OHDA group as compared to Sham group. A 
higher magnification photo was also provided 
for each photomicrograph as inset. (SNC and 
SNR = Substantianigra pars compacta and pars 
reticulate, respectively).*p < 0.05, **p < 0.01, *** 
p <0.005 (versus Sham); #p < 0.05, ## p < 0.01 
(versus 6-OHDA).
The results of TH-immunohistochemical 
staining (Figure 3) showed that there is no 
significant difference amongst sham, sham + 
BBR25, and sham + BBR50 groups regarding 
the number of TH-positive neurons on the left 
side of SNC. In addition, a significant reduction 
was observed in 6-OHDA-lesioned group (p < 
0.01) and a less significant reduction in 6-OHDA 
+ BBR25 (p < 0.01) and 6-OHDA + BBR50 
when compared to sham group. In this respect, 
the number of TH-positive neurons on the left 
side of SNC was significantly higher in 6-OHDA 
+ BBR50in comparison with 6-OHDA-lesioned 
group (p < 0.01).
In this study, we demonstrated that 
BBRpretreatment at a dose of 50 mg/kg could 
significantly decrease apomorphine-induced 
rotations, attenuate loss of Nissl-stained 
SNC neurons and prevent the reduction of 
TH immunoreactivity in SNC dopaminergic 
neurons.
The preferentialdamage of dopaminergic 
neurons in patients with PD is attributed to a 
genetically and/or environmentally-induced 
neurodegenerative process (17). In addition, 
6-OHDA, which is generally used for PD 
induction in rats, is assumed to cause selective 
degeneration of dopaminergic neurons (18). 
The unilateral damage of the nigrostriatal 
dopaminergic system through intrastriatal 
injection of 6-OHDA is followed by a reduction 
in the striatal dopamine level and an upregulation 
of dopaminergic postsynaptic receptors at the 
same side. These changes produce a prominent 
functional and motor asymmetry that can be 
evaluated by direct-acting dopaminergic agonists 
like apomorphine (19). These rotations are 
considered as reliable indicators of nigrostriatal 
dopamine depletion (20). In this research study, 
a significant attenuation of the apomorphine-
induced rotational behavior was observed in 
BBR50-pretreated 6-OHDA-lesioned group after 
1 week. The observed attenuation of rotational 
behavior in BBR50-pretreated 6-OHDA group 
could be due to theneuroprotective effect of 
BBR against SNC neuro degeneration and 
maintenance of striatal dopamine at a level that 
is not accompanied with a marked rotational 
behavior. In other words, nigrostriatal neurons 
within SNC were mainly preserved in the 
presence of BBR against neurodegenerative 
effects induced by the neurotoxin 6-OHDA.In 
support of our findings, in an earlier report, 
BBR was able to protect human dopaminergic 
neurons against 6-OHDA neurotoxicity through 
the induction of heme oxygenase-1 (15).
In addition, overproduction of free radicals, 
especially reactive oxygen speciesisalsoinvolved 
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Figure 2. Total number of Nissl-stained neurons on the left side of substantianigra pars compacta (SNC) at different interaural planes 
(upper panel) and its averaged number at all planes (lower panel) 1 week after the surgery.
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Figure 3. Averaged total number of TH-positive neurons on the left side of substantianigra pars compacta (SNC) 1 week after the surgery 
(upper panel) and midbrain photomicrographs showing TH-positive immunoreactive neurons within SNC. Arrows show reduction of 
TH-positive neurons in 6-OHDA-lesioned group. A higher magnification photo was also provided for each photomicrograph as inset.
*p < 0.05, **p < 0.01, *** p < 0.005(versus Sham); #p < 0.05, ## p < 0.01 (versus 6-OHDA).
in 6-OHDA-induced neurodegeneration (20). 
Oxidative stress is an important factor that could 
affect the survival of dopaminergic neurons in 
PD. Neurons mostly depend on energy produced 
by mitochondria and are simultaneously faced 
with high levels of reactive oxygen species as 
well as increased levels of free iron, which can 
promote hydroxyl production (21). Overload 
of the free radical formation may lead to cell 
death. In addition, auto-oxidation of dopamine 
may produce dopamine quinine (22). Formation 
of species such as semiquinones and other free 
radicals could especially damage nucleic acids, 
proteins, and membrane lipid components (23). 
Therefore, the therapeutic approaches are aimed 
at attenuation of oxidative stress. Free radical 
scavengers may also be helpful in prolonging 
survival time of dopaminergic neurons (24). 
Although in this study, we did not measure 
oxidative stress markers, but it is possible that 
BBR could have attenuated neuronal damage 
and loss through counteracting oxidative stress, 
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possibly via regulating antioxidant defense 
system as well as inhibition of free radical 
generation, as shown before (12). This requires 
further investigation.
Inflammatory process initiated in the brain 
tissue is also an important causative factor for 
the PD pathogenesis (25, 26). Pro-inflammatory 
cytokines released from glial cells could stimulate 
nitric oxide production and exert a deleterious 
effect on dopaminergic neurons by activating 
receptors that contain intra-cytoplasmic death 
domains involved in apoptotic pathway (27). It 
has been shown that BBR has anti-inflammatory 
activity and inhibits lipopolysaccharide-induced 
inflammatory processes (28). It is possible 
that BBR may have lowered the level of these 
inflammatory mediators within the brain, 
which itself contributes to neuroprotection in 
6-OHDA-induced PD model in rats, as observed 
in our study. Apoptosis is another factor that 
plays a critical role when cells are exposed to 
neurotoxins including 6-OHDA (29). BBR could 
have suppressed 6-OHDA-induced reactive 
oxygen speciesgeneration and apoptosis (11).
In contrast to our results, a study by Kwon 
etalhasshown that post-lesion treatment of 
6-OHDA-lesioned rats with BBR did not show 
any improvement in apomorphine-induced 
rotations and was not capable of restoring 
dopamine level and tyrosine hydroxylase level 
(14). In that study, the restorative and not the 
neuro protective potential of BBR was evaluated 
and for this reason, BBR was not capable to 
improve the condition when used after lesioning 
the nigrostriatal system. In our study, BBR was 
administered as a neuroprotective agent before 
lesioning this system and for this reason, our 
obtained results are different from those of 
Kwon et al.
In summary, these results indicate that pre-
lesion administration of BBR at a dose of 50 mg/
kg could protect against 6-OHDA toxicity and 
this may be of benefit besides other available 
therapies in PD.
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